Results 191 to 200 of about 677,503 (281)

New somatostatin analogs: will they fulfil old promises? [PDF]

, 2002
Hofland, L.J. (Leo), Lamberts, S.W.J. (Steven), Lely, A-J. (Aart-Jan) van der   +2 more
core   +1 more source

Somatostatin analogs modulate AIP in somatotroph adenomas: the role of the ZAC1 pathway.

Journal of Clinical Endocrinology and Metabolism, 2012
H. Chahal, G. Trivellin, C. Leontiou, Neda Alband, R. Fowkes, Asil Tahir, Susana Igreja, J. Chapple, S. Jordan, A. Lupp, S. Schulz, O. Ansorge, N. Karavitaki, E. Carlsen, J. Wass, Ashley B. Grossman, Ashley B. Grossman, M. Korbonits   +17 more
semanticscholar   +1 more source

Pathological complete response of initially unresectable multiple liver metastases achieved using combined peptide receptor radionuclide therapy and somatostatin analogs following pancreatic neuroendocrine tumor resection: a case report. [PDF]

Surg Case Rep
Umino R, Nara S, Kobayashi N, Mizui T, Takamoto T, Ban D, Esaki M, Hiraoka N, Shimada K.   +8 more
europepmc   +1 more source

The clinical use of somatostatin analogues in the treatment of cancer [PDF]

, 1990
Klijn, J.G.M. (Jan), Krenning, E.P. (Eric), Lamberts, S.W.J. (Steven), Reubi, J.-C. (Jean-Claude)   +3 more
core   +1 more source

Antitumor effects of somatostatin analogs in neuroendocrine tumors.

The Oncologist, 2012
L. Sidéris, P. Dubé, A. Rinke
semanticscholar   +1 more source

Predictors of Quality of Life in Acromegaly: No Consensus on Biochemical Parameters [PDF]

, 2017
Alberto M. Pereira, Caroline Sievers, Cornelie D. Andela, Günter K. Stalla, Nienke R. Biermasz, Victor J. Geraedts, Wouter R. van Furth   +6 more
core   +1 more source

Clinical review: Current scientific rationale for the use of somatostatin analogs and mTOR inhibitors in neuroendocrine tumor therapy.

Journal of Clinical Endocrinology and Metabolism, 2012
C. Bousquet, C. Lasfargues, M. Chalabi, Siham Moatassim Billah, C. Susini, D. Vezzosi, P. Caron, S. Pyronnet   +7 more
semanticscholar   +1 more source

Evaluation of the Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Inadequately Controlled With First-Generation Somatostatin Analogs. [PDF]

Front Endocrinol (Lausanne), 2019
Gadelha M, Bex M, Colao A, Pedroza García EM, Poiana C, Jimenez-Sanchez M, Yener S, Mukherjee R, Bartalotta A, Maamari R, Raverot G.   +10 more
europepmc   +1 more source